Oramed Pharmaceuticals Inc. (ORMP)
After hours:
Oramed Pharmaceuticals Inc.
1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
844 967 2633
https://www.oramed.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman | 754.3k | N/A | 1974 |
| Mr. David Silberman CPA | CFO & Treasurer | 259.53k | N/A | 1984 |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director | 503.95k | N/A | 1940 |
| Mr. Joshua Hexter | Chief Operating & Business Officer | 326.94k | N/A | 1970 |
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Corporate governance
Oramed Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
